Benzinga's Top Pre-Market NASDAQ Gainers (OREX, VVUS, RYAAY, AAPL)

Orexigen Therapeutics Inc OREX rose 148.74% to $11.84 in the pre-market session. A Food and Drug Administration (FDA) panel has recommended the approval of OREX' weight loss drug Contrave. VIVUS Inc VVUS added 17.56% to $9.17 in pre-market trading. VVUS reported positive outcome from phase 3 study of avanafil, for the treatment of erectile dysfunction. Ryanair Holdings plc RYAAY moved up 2.21% to $31 in pre-market trading. RYAAY's PEG ratio is 0.92. Apple Inc AAPL gained 0.34% to $319.28 in the pre-market session. AAPL's trailing-twelve-month ROE is 35.28%. Read more from Benzinga's Markets.